Alzheimer’s disease

Clinical Updates OB/GYN & Women's Health

Reproductive Lifespan and Hormonal Therapy in Relation to Later-Life Neurovascular Health in Community-Dwelling Older Women: An Evidence-Based Review

By MedXY 11/11/2026

This review synthesizes evidence linking lifetime estrogen exposure—both endogenous and exogenous—with neurovascular integrity and Alzheimer's disease risk in older women, highlighting the impact of reproductive lifespan and hormone therapy.

Clinical Updates Dentistry Infectious Diseases Neurology

Porphyromonas gingivalis-Induced NETs: A Bridge Between Periodontitis and Alzheimer’s Disease via TLR4 Activation

By MedXY 11/07/2026

This study elucidates how Porphyromonas gingivalis-induced neutrophil extracellular traps (NETs) contribute to neuroinflammation and cognitive impairment through TLR4 activation, revealing a mechanistic link between periodontitis and Alzheimer's disease progression.

Neurology news

Disparities in Utilization and Adherence to Antiamyloid Therapies in Alzheimer’s Disease and Mild Cognitive Impairment

By MedXY 10/26/2026

This study reveals that younger, non-Hispanic White patients with fewer comorbidities and lower socioeconomic vulnerability are more likely to receive antiamyloid medications for Alzheimer’s, while higher comorbidity predicts lower initial adherence.

Neurology news

Predictive Value of Midlife and Late-Life Blood Biomarkers for Alzheimer’s Disease and Long-Term Cognitive Decline

By MedXY 10/22/2026

This study reveals that midlife plasma p-tau181 predicts faster memory decline over 11 years, highlighting a long prodromal phase of Alzheimer’s disease. Late-life biomarkers p-tau181, NfL, and GFAP correlate with accelerated cognitive decline across domains.

Infectious Diseases Neurology news

Exploring the Link Between Common Infections and Alzheimer’s Disease Neuropathology: Insights From a UK Prospective Cohort Study

By MedXY 10/21/2026

A large-scale UK cohort study found no strong associations between antibodies against multiple common infections and key Alzheimer’s disease neuropathologies, though possible interactions with APOE ε4 genotype and education warrant further research.

Clinical Updates Neurology news Pathology & Lab Medicine

Earlier Disclosure of Blood-Based Biomarkers Enhances Diagnostic Certainty and Clinical Management in Cognitive Disorders: A Review of a Recent Randomized Clinical Trial

By MedXY 10/09/2026

Early disclosure of plasma p-tau217 and NfL biomarkers significantly improves diagnostic confidence and clinical decisions in cognitive decline without increasing emotional distress, supporting their integration into routine memory clinic care.

Clinical Updates Neurology news Pathology & Lab Medicine

Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers: Implications for Diagnosis and Management

By MedXY 10/07/2026

This review synthesizes evidence on clinical and biological factors linked to discordance between plasma p-tau217 and standard AD biomarkers, highlighting implications for diagnosis, patient stratification, and future biomarker development.

Clinical Updates news Otorhinolaryngology

Hearing Loss and Regional Brain Amyloid Deposition: Insights from In Vivo PET Imaging and Neuropathological Correlates

By MedXY 10/01/2026

This review synthesizes evidence linking hearing loss to regional brain amyloid deposition, highlighting recent in vivo PET findings, meta-analytic data on AD neuropathology, and amyloid-related inner ear pathology, discussing potential mechanisms and future research directions.

Neurology news

Dynamic Plasma Biomarkers Reveal Multifaceted Effects of Lecanemab in Early Alzheimer’s Disease

By MedXY 09/29/2026

This longitudinal study investigates plasma biomarker dynamics in Alzheimer's patients treated with lecanemab, revealing distinct biomarker trajectories that reflect amyloid clearance, tau modulation, and immune responses, offering insights into treatment monitoring and prognostication.

Neurology news Radiology

A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease

By MedXY 09/23/2026

This study introduces a standardized 5-class framework for tau PET imaging to better detect and stage Alzheimer’s disease, improving early diagnosis and patient stratification across different tracers.

Internal Medicine Neurology news

Integrating Plasma p-tau217 and APOE Genotype to Predict Cognitive Decline Across Diverse Populations

By MedXY 09/13/2026

This pooled analysis of seven multi-ethnic cohorts demonstrates the combined prognostic value of plasma phosphorylated tau 217 concentrations and APOE-ε4 genotype for predicting risk and timing of cognitive impairment, emphasizing biomarker-guided strategies prior to symptom onset.

Neurology news

Unraveling Alzheimer’s Disease Progression in Down Syndrome via Blood Proteome Dynamics

By MedXY 09/05/2026

Longitudinal analysis of blood proteins reveals distinctive trajectories and associations with cognitive decline in adults with Down syndrome, shedding light on Alzheimer's disease pathophysiology in this high-risk group.

Neurology news Pathology & Lab Medicine/Bệnh học

Plasma Biomarkers for Neocortical Tau Burden

By MedXY 08/15/2026

A multiprotein plasma panel improves detection of advanced neocortical tau pathology in Alzheimer’s disease risk individuals beyond p-tau217 alone, enhancing patient stratification and clinical trial selection.

Cardiology Clinical Updates Neurology news

Oral Anticoagulants, Cognition, and Clinical Outcomes in Atrial Fibrillation and Alzheimer’s Disease: Insights from a Swedish Nationwide Study

By MedXY 08/13/2026

This review synthesizes evidence linking NOAC use to slower cognitive decline and improved clinical outcomes in patients with atrial fibrillation and Alzheimer's disease, highlighting advantages over warfarin and non-use.

Neurology news Pathology & Lab Medicine/Bệnh học

Discriminating Prion Diseases from Alzheimer’s Disease Using Plasma Biomarkers: The Crucial Role of NfL/p-tau217 Ratio

By MedXY 07/14/2026

Plasma phosphorylated tau biomarkers overlap in Alzheimer’s and prion diseases, risking diagnostic confusion. The NfL/p-tau217 ratio emerges as an accurate plasma biomarker to distinguish prion diseases from Alzheimer’s, improving diagnostic precision and guiding appropriate clinical management.

Clinical Updates Neurology news Pathology & Lab Medicine

Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers: Diagnostic Challenges and Clinical Implications

By MedXY 07/01/2026

This review examines the impact of traumatic brain injury on the accuracy of Alzheimer disease blood biomarkers, highlighting reduced diagnostic performance in TBI-affected populations and the implications for clinical interpretation.

Neurology news OB/GYN & Women’s Health

Influence of Parity on Cognitive Decline and Hippocampal Atrophy in Amyloid-Positive Postmenopausal Women

By MedXY 06/25/2026

Higher parity in cognitively unimpaired postmenopausal women with positive β-amyloid status is linked to accelerated cognitive decline and hippocampal volume reduction, suggesting parity modulates resilience to Alzheimer’s pathology in preclinical stages.

Neurology news

Identification of Genetic Modifiers of Autosomal Dominant Alzheimer’s Disease: A Genome-Wide Association Study

By MedXY 06/10/2026

A genome-wide study identified three genetic modifiers of autosomal dominant Alzheimer’s disease, linking them to disease risk, earlier onset, and biomarker changes involving amyloid, tau, TDP-43, and brain aging.

Neurology news Pathology & Lab Medicine

Women’s Elevated P-Tau217 Levels and Faster Cognitive Decline: Implications for Preclinical Alzheimer’s Disease

By MedXY 04/28/2026

Women with high amyloid-β show higher p-tau217 levels and faster tau accumulation than men, leading to greater cognitive decline. This sex-specific tau response may redefine preclinical Alzheimer's diagnostics and therapeutics.

Neurology news Pathology & Lab Medicine

Sex-Specific Differences in P-Tau217 and Tau Aggregation: Implications for Preclinical Alzheimer’s Disease

By MedXY 04/28/2026

Women exhibit higher plasma p-tau217 levels and tau aggregation than men in amyloid-positive individuals, suggesting sex-specific pathways in Alzheimer’s disease progression.